Back

Effect of vutrisiran in patients with and without atrial fibrillation or flutter: analysis from HELIOS-B

11 May 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Xiaowen Wang

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF
Doctor C. Emter (Boulder, US)
Abstract Slides Video
Presentation thumbnail
Prevalence and prognostic implications of frailty and other geriatric conditions in patients with transthyretin amyloid cardiomyopathy. The AMYLO-FRAIL study.
Doctor M. Antunez-Ballesteros (Coruna, A, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Silencing TTR, distinct signals: safety profiles of small interfering RNA therapies in amyloidosis
Mrs J. Gu (Erie, US)
Abstract Slides Video
Presentation thumbnail
Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: pooled analysis of vutrisiran and patisiran data
Doctor M. Maurer (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment

The Event

Event poster

Heart Failure 2026

11 May 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
HELIOS-B: Vutrisiran reduces all-cause mortality
thumbnail
Congress Presentation
HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources